Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Neurology
Authors: Nilo Riva, Gabriele Mora, Gianni Sorarù, Christian Lunetta, Ottavia E Ferraro, Yuri Falzone, Letizia Leocani, Raffaella Fazio, Mauro Comola, Giancarlo Comi, Fabio Formaglio, Paolo Rossi, Marta Clerici, Yuri Matteo Falzone, Laura Pozzi, Daniele Martinelli, Federica Cerri, Ignazio Diego Lopez, Filippo Martinelli-Boneschi, Angelo Quattrini, Elisabetta Pieri, Kalliopi Marinou, Giorgia Querin, Valeria Sansone, Eleonora Maestri, Andrea Calvo, Adriano Chio
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: nabiximols, cannabinoids, spasticity, motor neuron disease, amyotrophic lateral sclerosis, primary lateral sclerosis, oromucosal spray, delta-9-tetrahydrocannabinol, cannabidiol, Modified Ashworth Scale, drug safety and tolerability, self-titration, quality of life, disability progression, neuromodulation
Open Access status: green
OpenAlex ID: W2905561928
